Country: United States
Language: English
Source: NLM (National Library of Medicine)
SUCRALFATE (UNII: XX73205DH5) (SUCRALFATE - UNII:XX73205DH5)
VistaPharm, LLC
SUCRALFATE
SUCRALFATE 1 g in 10 mL
ORAL
PRESCRIPTION DRUG
Sucralfate Oral Suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer. Sucralfate Oral Suspension is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients.
Sucralfate Oral Suspension, 1 g/10 mL is a pink suspension supplied as follows: NDC 66689-790-01: 10 mL unit-dose cup NDC 66689-790-30: Case contains 30 unit-dose cups of 10 mL (NDC 66689-790-01), packaged in 3 trays of 10 unit-dose cups each. NDC 66689-790-40: Case contains 40 unit-dose cups of 10 mL (NDC 66689-790-01), packaged in 4 trays of 10 unit-dose cups each. NDC 66689-790-50: Case contains 50 unit-dose cups of 10 mL (NDC 66689-790-01), packaged in 5 trays of 10 unit-dose cups each. NDC 66689-790-99: Case contains 100 unit-dose cups of 10 mL (NDC 66689-790-01), packaged in 10 trays of 10 unit-dose cups each. SHAKE WELL BEFORE USING. AVOID FREEZING. Store at controlled room temperature 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature]. Rx Only Distributed by: VistaPharm, Inc. Largo, FL 33771, USA VP1059R10 02/2020
New Drug Application
SUCRALFATE- SUCRALFATE SUSPENSION VISTAPHARM, LLC ---------- SUCRALFATE ORAL SUSPENSION Rx only DESCRIPTION Sucralfate Oral Suspension contains sucralfate and sucralfate is an α-D- glucopyranoside, β-D-fructofuranosyl-, octakis-(hydrogen sulfate), aluminum complex. SucralfateOral Suspension for oral administration contains 1 g of sucralfate per 10 mL. SucralfateOral Suspension also contains: colloidal silicon dioxide NF, FD&C Red #40, flavor, glycerin USP, methylcellulose USP, methylparaben NF, microcrystalline cellulose NF, purified water USP, simethicone USP, and sorbitol solution USP. Therapeutic category: antiulcer. CLINICAL PHARMACOLOGY Sucralfate is only minimally absorbed from the gastrointestinal tract. The small amounts of the sulfated disaccharide that are absorbed are excreted primarily in the urine. Although the mechanism of sucralfate's ability to accelerate healing of duodenal ulcers remains to be fully defined, it is known that it exerts its effect through a local, rather than systemic, action. The following observations also appear pertinent: 1. Studies in human subjects and with animal models of ulcer disease have shown that sucralfate forms an ulcer-adherent complex with proteinaceous exudate at the ulcer site. 2. _ In vitro_, a sucralfate-albumin film provides a barrier to diffusion of hydrogen ions. 3. In human subjects, sucralfate given in doses recommended for ulcer therapy inhibits pepsin activity in gastric juice by 32%. _In vitro_, sucralfate adsorbs bile salts. These observations suggest that sucralfate's antiulcer activity is the result of formation of an ulcer-adherent complex that covers the ulcer site and protects it against further attack by acid, pepsin, and bile salts. There are approximately 14 to 16 mEq of acid- neutralizing capacity per 1 g dose of sucralfate. CLINICAL TRIALS In a multicenter, double-blind, placebo-controlled study of Sucralfate Oral Suspension, a dosage regimen of 1 gram (10 mL) four times daily was demonstrated to be superior to placebo in ulcer healing. RE Read the complete document